首页 | 本学科首页   官方微博 | 高级检索  
检索        


Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized,open-label,phase 3 CheckMate 025 trial
Authors:Robert J Motzer MD  Bernard Escudier MD  Saby George MD  Hans J Hammers MD  PhD  Sandhya Srinivas MD  Scott S Tykodi MD  PhD  Jeffrey A Sosman MD  Elizabeth R Plimack MD  Giuseppe Procopio MD  David F McDermott MD  Daniel Castellano MD  Toni K Choueiri MD  Frede Donskov MD  PhD  Howard Gurney MD  Stéphane Oudard MD  Martin Richardet MD  PhD  Katriina Peltola MD  PhD  Ajjai S Alva MD  Michael Carducci MD  John Wagstaff MD  Christine Chevreau MD  Satoshi Fukasawa MD  Yoshihiko Tomita MD  PhD  Thomas C Gauler MD  Christian K Kollmannsberger MD  Fabio A Schutz PhD  James Larkin MD  PhD  David Cella PhD  M Brent McHenry PhD  Shruti Shally Saggi BEng
Institution:1. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York;2. Department of Medical Oncology, Gustave Roussy, Villejuif, France;3. Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York;4. Division of Hematology and Oncology, UT Southwestern Kidney Cancer Program, Dallas, Texas;5. Stanford Cancer Institute, Stanford University Medical Center, Stanford, California;6. Department of Medicine, University of Washington and Fred Hutchinson Cancer Research Center, Seattle, Washington;7. Department of Hematology/Oncology, Northwestern University Medical Center, Chicago, Illinois;8. Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania;9. Fondazione Istituto Nazionale Tumori, Milan, Italy;10. Beth Israel Deaconess Medical Center, Dana-Farber/Harvard Cancer Center, Boston, Massachusetts;11. Oncologia Medica, Hospital Universitario 12 De Octubre, Madrid, Spain;12. Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts;13. Department of Oncology, Aarhus University Hospital, Aarhus, Denmark;14. Department of Medical Oncology, Westmead Hospital and Macquarie University, Westmead, New South Wales, Australia;15. Service de Cancérologie Médicale, Hôpital Européen Georges Pompidou, Assistance Publique–Hôpitaux de Paris, Paris, France;16. Fundacion Richardet Longo, Instituto Oncologico de Cordoba, Cordoba, Argentina;17. Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland;18. Division of Hematology and Oncology, University of Michigan, Ann Arbor, Michigan;19. Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medicine, Baltimore, Maryland;20. South West Wales Cancer Institute and Swansea University College of Medicine, Swansea, United Kingdom;21. Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse - Oncopole, Toulouse, France;22. Prostate Center and Division of Urology, Chiba Cancer Center, Chiba, Japan;23. Department of Urology, Department of Molecular Oncology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan;24. Department of Medicine, University Hospital Essen, University of Duisburg-Essen, Duisburg, Germany;25. Division of Medical Oncology, BC Cancer–Vancouver Cancer Centre, Vancouver, British Columbia, Canada;26. Beneficencia Portuguesa de São Paulo, São Paulo, Brazil;27. Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom;28. Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois;29. Department of Biostatistics, Bristol Myers Squibb, Princeton, New Jersey;30. Department of Clinical Trials, Bristol Myers Squibb, Princeton, New Jersey;31. Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
Abstract:
Keywords:advanced renal cell carcinoma (aRCC)  CheckMate 025  everolimus  immune checkpoint inhibitor  nivolumab  previously treated
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号